These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24497461)

  • 1. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T
    Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
    Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL; Stalbovskaya V; Jones B
    Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J; Li Y; Zhu L
    J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry.
    Yoshida M; Matsuyama Y
    J Biopharm Stat; 2016; 26(5):842-58. PubMed ID: 26391147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing therapeutic cancer vaccine trials with delayed treatment effect.
    Xu Z; Zhen B; Park Y; Zhu B
    Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
    Kaneko Y; Morita S
    J Biopharm Stat; 2024 Aug; 34(5):626-645. PubMed ID: 37585719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.
    Garès V; Andrieu S; Dupuy JF; Savy N
    Stat Med; 2015 Feb; 34(4):541-57. PubMed ID: 25388274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
    Kundu MG; Sarkar J
    Stat Med; 2021 May; 40(10):2321-2338. PubMed ID: 33624861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical and practical considerations in designing of immuno-oncology trials.
    Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
    J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yang M; Hua Z; Xue L; Hu M
    J Biopharm Stat; 2020 Mar; 30(2):244-266. PubMed ID: 31288599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S; Chu C; Rong A
    Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy trial design with delayed treatment effect.
    Wu J; Wei J
    Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
    Prior TJ
    Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.